Clinical Trial

Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This multi-center, observational, post-intervention long term follow-up (LTFU) study will monitor for safety and efficacy of AAVAnc80-hOTOF in individuals with sensorineural hearing loss due to otoferlin gene mutations who have previously received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-11-19; most recent amendment 2026-04-01.
Trial Details
NCT Number NCT06696456
Lead Sponsor Akouos, Inc.
Collaborators: Eli Lilly and Company
Conditions Otoferlin Gene-mediated Hearing Loss
Enrollment 30 participants
Start Date 2024-11-11
Primary Completion 2033-04 (estimated)
Study Completion 2033-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-06